Evidence map›Paper›PMID 34412597›Full record

ArticleBMC infectious diseases2021

Bacteria and viruses in the upper respiratory tract of Congolese children with radiologically confirmed pneumonia.

Archippe M Birindwa, Jerry K Kasereka, Lucia Gonzales-Siles, Shadi Geravandi, Mambo Mwilo, Léonard K Tudiakwile, Néné L Mwinja, Balthazar Muhigirwa, Théophile Kashosi, Jeanière T Manegabe and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Impact of influenza virus infection on lung microbiome in adults with severe pneumonia.Annals of clinical microbiology and antimicrobials · 2023
    Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Archippe M BirindwaDepartment of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden. birindwaarchippe@gmail.com.ORCID https://orcid.org/0000-0002-0666-9763
Jerry K KaserekaPanzi Hospital, Bukavu, Democratic Republic of the Congo.
Lucia Gonzales-SilesDepartment of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Shadi GeravandiDepartment of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Mambo MwiloPanzi Hospital, Bukavu, Democratic Republic of the Congo.
Léonard K TudiakwilePanzi Hospital, Bukavu, Democratic Republic of the Congo.
Néné L MwinjaPanzi Hospital, Bukavu, Democratic Republic of the Congo.
Balthazar MuhigirwaPanzi Hospital, Bukavu, Democratic Republic of the Congo.
Théophile KashosiUniversité Evangélique en Afrique, Bukavu, Democratic Republic of the Congo.
Jeanière T ManegabePanzi Hospital, Bukavu, Democratic Republic of the Congo.
Elie B BugashanePanzi Hospital, Bukavu, Democratic Republic of the Congo.
Stay M SailiPanzi Hospital, Bukavu, Democratic Republic of the Congo.
Clement MungoPanzi Hospital, Bukavu, Democratic Republic of the Congo.
Rickard NordénDepartment of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Rune AnderssonDepartment of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Susann SkovbjergDepartment of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Kinshasa General Hospital · CDSahlgrenska University Hospital · SEUniversity of Gothenburg · SEUniversité Evangélique en Afrique · CD

Funding

TRAINEESHIPS IN AIDS PREVENTION STUDIEST32MH019105 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carol Suzanne Camlin, Glenn-Milo Santos · 1989 to 2026
$15.3M
NIMH NIH HHS T32 MH019105
6 · The paper itself

Abstract

backgroundAcute pneumonia remains a leading cause of death among children below 5 years of age in the Democratic Republic of the Congo (DR Congo), despite introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in 2013. Potential pathogens in the nasopharynx of hospitalised children with pneumonia have not been studied previously in DR Congo. Here we compare clinical characteristics, risk factors and nasopharyngeal occurrence of bacteria and viruses between children with severe and non-severe pneumonia.

methodsBetween June 2015 and June 2017, 116 children aged from 2 to 59 months hospitalised due to radiologically confirmed pneumonia at Panzi referral university hospital, Bukavu, Eastern DR Congo were included in the study and sampled from nasopharynx. A multiplex real-time PCR assay for detection of 15 different viruses and 5 bacterial species was performed and another multiplex PCR assay was used for pneumococcal serotype/serogroup determination.

resultsDuring the study period 85 (73%) of the children with radiologically confirmed pneumonia met the WHO classification criteria of severe pneumonia and 31 (27%) had non-severe pneumonia. The fatality rate was 9.5%. Almost all (87%) children were treated with antibiotics before they were hospitalised, in most cases with amoxicillin (58%) or trimethoprim-sulfamethoxazole (20%). The frequency of potential pathogens in the nasopharynx of the children was high, and any viral or bacterial nucleic acids present at high levels, irrespective of species or type, were significantly associated with severe pneumonia as compared with non-severe cases (52% versus 29%, p = 0.032). White blood cell count > 20,000/μL and C-Reactive Protein > 75 mg/dL were associated with severe pneumonia at admission. Fatal outcome was in the multivariable analysis associated with having a congenital disease as an underlying condition. One or more pneumococcal serotypes/serogroups could be identified in 61 patients, and out of all identified serotypes 31/83 (37%) were non-PCV13 serotypes.

conclusionsThe occurrence of any bacteria or any viruses at high levels was associated with severe pneumonia at admission. Children with congenital disorders might need a higher attention when having symptoms of acute respiratory infection, as developed pneumonia could lead to fatal outcome.

Indexed as

Pneumococcal InfectionsPneumoniaVirusesBacteriaChildHumansInfantNasopharynxPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugatePneumococcal VaccinesVaccines, ConjugateBacteriaDemocratic Republic of the CongoHospitalised childrenNasopharynxPneumococcal serotypes/serogroupsRadiologically confirmed pneumoniaViruses

Identifiers

PMID34412597
PMCPMC8374414
OpenAlexW3195593551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.